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Efficacy and acceptability of
pharmacological and non-pharmacological
interventions for non-specific chronic low
back pain: a protocol for a systematic
review and network meta-analysis
Trevor Thompson1* , Sofia Dias2, Damian Poulter1, Sharon Weldon3,4, Lucy Marsh1, Claire Rossato1, Jae Il Shin5,
Joseph Firth6,7, Nicola Veronese8, Elena Dragioti9, Brendon Stubbs10, Marco Solmi11, Christopher G. Maher12,
Andrea Cipriani13,14 and John P. A. Ioannidis15
Abstract
Background: Despite the enormous financial and humanistic burden of chronic low back pain (CLBP), there is little
consensus on what constitutes the best treatment options from a multitude of competing interventions. The
objective of this network meta-analysis (NMA) is to determine the relative efficacy and acceptability of primary care
treatments for non-specific CLBP, with the overarching aim of providing a comprehensive evidence base for
informing treatment decisions.
Methods: We will perform a systematic search to identify randomised controlled trials of interventions endorsed in
primary care guidelines for the treatment of non-specific CLBP in adults. Information sources searched will include
major bibliographic databases (MEDLINE, Embase, CENTRAL, CINAHL, PsycINFO and LILACS) and clinical trial
registries. Our primary outcomes will be patient-reported pain ratings and treatment acceptability (all-cause
discontinuation), and secondary outcomes will be functional ability, quality of life and patient/physician ratings of
overall improvement. A hierarchical Bayesian class-based NMA will be performed to determine the relative effects of
different classes of pharmacological (NSAIDs, opioids, paracetamol, anti-depressants, muscle relaxants) and non-
pharmacological (exercise, patient education, manual therapies, psychological therapy, multidisciplinary approaches,
massage, acupuncture, mindfulness) interventions and individual treatments within a class (e.g. NSAIDs: diclofenac,
ibuprofen, naproxen). We will conduct risk of bias assessments and threshold analysis to assess the robustness of
the findings to potential bias. We will compute the effect of different interventions relative to placebo/no treatment
for both short- and long-term efficacy and acceptability.
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Discussion: While many factors are important in selecting an appropriate intervention for an individual patient,
evidence for the analgesic effects and acceptability of a treatment are key factors in guiding this selection. Thus,
this NMA will provide an important source of evidence to inform treatment decisions and future clinical guidelines.
Systematic review registration: PROSPERO registry number: CRD42019138115
Keywords: Low back pain, Network meta-analysis, Systematic review, Protocol, Randomized controlled trial
Background
Low back pain is the leading cause of years lived with
disability across the world [30]. It is also the second
most common reason reported by patients for visiting
their family doctor [24] and has an estimated lifetime
prevalence of 80% [59]. The most common type of low
back pain by far is the non-specific type [2], indicating
the absence of an identifiable cause. While acute epi-
sodes of non-specific low back pain can improve mark-
edly in the first 6 weeks, recent estimates suggest that
pain can persist for over 12 weeks in 24–61% of cases
[12]. This type of chronic low back pain (CLBP) carries
an enormous economic burden both from direct (e.g.
treatment) and indirect (e.g. lost work productivity)
costs. In the UK, the cost to the NHS from low back
pain exceeds £12 billion a year (NatCen Social [45]),
with the chronic form representing the largest propor-
tion of these costs [6]. CLBP is also associated with im-
paired quality of life, mobility and daily function as well
as social isolation, disability and depression [46].
Because the underlying pathology of non-specific
CLBP is by definition unidentified, treatment is largely
focused on reducing pain symptoms, and a range of
pharmacological and non-pharmacological intervention
strategies are used in clinical practice [39]. A recent re-
view of international practice guidelines [47] found that
while NSAIDs and exercise were commonly recom-
mended, the endorsement of many other treatments in-
cluding opioids, antidepressants, paracetamol, muscle
relaxants, spinal manipulation and acupuncture varied
considerably across guidelines. The apparent uncertainty
over which pool of interventions constitute the most ef-
fective options for treating non-specific CLBP suggests
the need for a stronger evidence base.
Network meta-analysis (NMA) provides a powerful
means of assessing multiple competing interventions by
synthesising data across a network of different treat-
ments [15]. By incorporating indirect evidence (where
two treatments can be compared by assessing their per-
formance relative to a common comparator such as pla-
cebo), the relative effects of two interventions can be
evaluated even when no head-to-head trials are available.
This cannot be achieved with standard pairwise meta-
analysis and helps to establish a hierarchy of the best in-
terventions for a particular condition. In addition, where
there is both direct and indirect evidence, these can be
combined using all the available evidence to compute
the relative treatment effect.
The objective of this NMA is to assess the effective-
ness and acceptability of interventions endorsed in pri-
mary care practice guidelines for the treatment of non-
specific CLBP, with the aim of providing a comprehen-
sive evidence base to inform treatment decisions. The
project is called Study of Pain Interventions using Net-
work meta-Analysis: Low-back pain (SPINAL).
Methods/design
This protocol conforms to PRISMA-P [42] recommen-
dations (Additional file 1) and was developed based on
guidelines for systematic reviews of back pain interven-
tions from the Cochrane Back and Neck Group [26].
Eligibility criteria were developed using the PICOS
framework and are reported in detail in the following
sections and summarised briefly in Table 1.
Population
Inclusion criteria
We will include studies of adults (≥ 18 years) with non-
specific CLBP. This is typically defined as pain without a
specific known cause or pathology that persists for 12 or
more weeks and that occurs below the costal margin
and above the inferior gluteal folds.
Table 1 Summary of PICOS eligibility criteria (“Methods/design”
section lists detailed criteria)
Inclusion criteria Exclusion criteria
Population Adults (≥ 18 years)
with non-specific CLBP
Patient baseline pain
< 4/10; radicular pain
or LBP with a known
cause; LBP < 12 weeks
Intervention Primary care interventions
for CLBP
Surgical or invasive
interventional
procedures
Comparison A different eligible
intervention or a control
(placebo/sham or no
intervention)
Outcome Pain ratings or acceptability
(all cause discontinuation)
Study type Randomised clinical trials
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Studies that simply describe low back pain as non-
specific or chronic without providing detail of how
this was determined will be included, provided this
designation does not conflict with information else-
where in the text (e.g. where a specific cause of LBP
such as infection, cancer or fracture is listed, or
where there is an obvious non-chronic symptom dur-
ation). Where it cannot be reliably determined
whether LBP is specific or non-specific, we will as-
sume non-specific as this represents the vast majority
of LBP cases [47]. Where LBP duration cannot be re-
liably determined, we will assume LBP is acute and
exclude the study as it seems likely that any chron-
icity would have been referred to in the text; but we
will document such studies and include them as part
of a sensitivity analysis if there are > 5 such studies.
Exclusion criteria
We will exclude studies of LBP patients with radicular
pain, e.g. sciatica (or where > 10% of participants have ra-
dicular symptoms in mixed samples of patients with and
without radicular pain). Radicular symptoms are typically
a result of spinal nerve compromise and represent a popu-
lation that may require different treatment options and
who are commonly differentiated in treatment guidelines
[47]. To help ensure a consistent patient population, we
will exclude studies with a minimum baseline threshold
for individual patient eligibility that is below 4 on a 0–10
rating, unless separate data are available for participants
with baseline pain of 4 or above. We chose a threshold of
4 or above as this represents a common and established
individual patient entry criterion and will ensure a
homogenous sample of patients with pain of at least a
moderate, clinically meaningful level [4] who are the most
likely to seek treatment. If a trial does not specify individ-
ual baseline pain as an entry criterion, we will calculate z-
scores from the sample mean baseline pain using the for-
mula z = (mean baseline pain − 4.0)/SD and retain only
trials where z > − 1, indicating approximately 85% of pa-
tients reporting a baseline pain of 4 or more.
Whenever we encounter trials that include both eligible
and ineligible patients, we will try to determine whether
data on the eligible subset can be extracted separately (e.g.
in trials including both children and adults, separate the
adults; in trials including both patients with and without
sciatica, separate those without sciatica; in trials with base-
line pain both < 4 and ≥ 4, separate those with ≥ 4 pain;
and in trials with LBP duration both below and above 12
weeks, separate those with LBP ≥ 12 weeks). If the data for
the eligible subset are not available from the published pa-
pers and cannot be obtained from the authors, the entire
trial will be included, if the percentage of eligible patients
is expected to be more than 85% (as exemplified for the
baseline pain criterion above).
Interventions
We will include interventions for the treatment of CLBP
in primary care that are endorsed by any of the 15 clin-
ical practice guidelines reviewed by Oliveira et al. [47],
with the exception of herbal medicine as this is endorsed
by only one guideline (and recommended against in one
other guideline) and is often studied in trials of very low
quality [29]. Our rationale for focusing on treatments
only included in practice guidelines is that these repre-
sent the pool of intervention strategies more likely to be
adopted in clinical practice and because their presence
in guidelines usually indicates a higher quality evidence
base [47]. Surgical and interventional pain management
(e.g. spinal injections, radiofrequency denervation, deep
brain and spinal cord stimulation [43]) will be excluded
as these are invasive procedures that are recommended
for low back only as next-line treatment in secondary or
tertiary care for severe or refractory LBP where conser-
vative primary care treatments have failed, and are not
recommended in any guidelines when LBP is chronic
and non-specific [47].
Both single and combined treatments are considered eli-
gible, and medications may be fixed or flexibly dosed. For
medications approved for pain, we will include only trials
that use licenced dosing ranges based on European Medi-
cines Agency guidelines. Where a drug is used off-label
and no dosing guidelines exist for pain management, we
will include all such trials but perform sensitivity analysis
removing studies using dosages outside the approved dos-
ing range for that drug’s approved indication.
Classification of interventions
Treatments will be grouped into intervention classes to
allow us to compare the relative effects of intervention
classes as well as individual treatments within a class,
using a Bayesian hierarchical class-based NMA model
[18, 19]. Grouping individual treatments into meaningful
classes maximises statistical power and provides a sim-
pler and more interpretable framework on which to ul-
timately inform treatment decisions (comparing each
individual treatment with every other for 40 treatments,
for example, would result in 780 potential comparisons).
We will also perform separate analysis of pharmaco-
logical and non-pharmacological networks as described
in the “Network meta-analysis” section.
Initial classifications were informed by key reviews of
treatment guidelines for CLBP interventions [9, 25, 39, 46,
47, 56] and then circulated to seven members of the Lancet
Low Back Pain Series Working Group (not previously
known to the lead author) for evaluation and comment. We
received responses from five members (see the “Acknowl-
edgements” section), and subsequent refinements were
made resulting in a final set of classifications (Table 2).
Classifications are differentiated primarily by mechanisms of
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action, although when putative mechanisms were unclear
(e.g. acupuncture) or there was uncertainty over the most
appropriate classification, that treatment was listed in its
own class.
A non-exhaustive list of examples of the most common
interventions that comprise each class are given in Table 2.
Pharmacological interventions returned by searches that
are not listed in Table 2 will be classified based on MeSH
and emtree headings, and non-pharmacological interven-
tions will be classified after discussion with the review team
prior to analysis with rationale for these classifications doc-
umented in the final report.
In the absence of any definitive criteria for differentiat-
ing ‘weak’ vs. ‘strong’ opioids, we followed the classifica-
tions used by Whittle et al. [57] where strong opioids
are generally those with higher rates of conversion to mor-
phine. For topical pharmacological agents, while the
agents used (e.g. ibuprofen) are also often present in other
classes, we nevertheless assessed this as a distinct class
given the potential benefits of topical relative to systemic
administration. We defined exercise therapy as ‘a series of
specific movements with the aim of training or developing
the body by a routine practice or as physical training to
promote good physical health’ [1]. Although there are nu-
merous meaningful ways to categorise exercise types, we
decided on two basic classifications of non-specific and
mind-body type approaches. However, if excessive hetero-
geneity is observed within each exercise type relative to
other classes, we will explore sources of possible hetero-
geneity based on pre-defined exercise characteristics
Table 2 Intervention classes and individual treatments (generic drug names given for pharmacological agents)
Class Examples of individual treatments
Pharmacological
Antidepressants: SNRI Duloxetine, desvenlafaxine, levomilnacipran, venlafaxine, milnacipran
Antidepressants: SSRI Fluoxetine, fluvoxamine, paroxetine, escitalopram, citalopram, sertraline, vilazodone
Antidepressants: tricyclic Amitriptyline, amoxapine, desipramine, imipramine, doxepin, clomipramine, trimipramine,
protriptyline, imipramine, nortriptyline, doxepin, nortriptyline
NSAIDs Ibuprofen, naproxen, sulindac, ketoprofen, tolmetin, etodolac, fenoprofen, diclofenac,
flurbiprofen, piroxicam, ketorolac, Indomethacin, meloxicam, nabumetone, oxaprozin
mefenamic acid, diflunisal, fenoprofen
Opioids (strong) Morphine, hydromorphone, oxycodone, fentanyl, methadone, buprenorphine,
diamorphine, tapentadol
Opioids (weak) Codeine, hydrocodone, tramadol, pentazocine, tilidine
Muscle relaxants: benzodiazepines Diazepam, estazolam, quazepam, alprazolam, chlordiazepoxide, clorazepate,
lorazepam, flurazepam, clonazepam, temazepam, midazolam
Muscle relaxants: skeletal Flupirtin, orphenadrine, dantrolene, carisoprodol, tizanidine, incobotulinumtoxinA,
cyclobenzaprine, metaxalone, baclofen, methocarbamol, chlorzoxazone
Paracetamol
Topical agents (non-opioid) Diclofenac, capsaicin, lidocaine
Non-pharmacological treatments
Acupuncture Acupuncture, dry needling
Exercise: non-specific Walking, swimming, running, stretching, aerobics
Exercise: mind-body and bodily awareness Yoga, tai chi, Pilates, motor control exercise, alexander technique
Manual therapy: spinal manipulation High-velocity thrust techniques at or near the end of the passive or
physiologic range of motion
Manual therapy: spinal mobilisation Low-grade velocity movement techniques within the patient’s range of
motion and control
Massage Soft tissue massage, acupressure
Mindfulness Mindfulness, mindfulness-based stress reduction
Multidisciplinary approaches Packages that include coordinated delivery of interventions from across different
disciplinary practices/clinics (which typically consist of physical and psychological
therapy, e.g. education + physiotherapy + exercise + counselling)
Patient education: basic Back school (e.g. instruction on anatomy and function of the back), brief educational
intervention, advice on importance of staying active, reassurance, McKenzie therapy
Patient education: pain neuroscience Educational sessions that describe the neurobiology and neurophysiology of pain by
the nervous system
Psychological therapy CBT, operant therapy, behavioural therapy, self-regulatory therapy
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identified by Hayden et al. [33] as potentially important to
efficacy (including dose/intensity, supervised vs. non-
supervised, delivery type and design) and consider reclas-
sification if necessary. Finally, as no consensus could be
reached on the classification of McKenzie therapy, we pro-
visionally classified this as education as the approach in-
vokes components of several treatments, but we will
explore the impact of this decision in a sensitivity analysis.
Comparator
A different eligible individual treatment or a control
condition (placebo/sham or no-intervention).
Outcomes
Primary outcomes
(1) Pain intensity, assessed with an established rating
scale (e.g. 0–10 numerical rating scale or VAS) at
specific time periods defined below
(2) Acceptability, defined as (one minus) the
proportion of patients who discontinued treatment
during the trial for any reason
Assessment timing The effects of different interven-
tions on pain will be evaluated within the following dis-
tinct assessment windows: immediate (≤ 2 weeks post-
randomisation), short term (> 2 weeks to ≤ 3months),
medium term (> 3months to < 12 months) and long
term (≥ 12months). These time windows were selected
based on a sample of 24 eligible articles from provisional
searches. If these divisions fail to sensitively reflect the
pattern of assessment timings used across studies, we
may reclassify these windows prior to analysis to reflect
trial practices.
As many pharmacological interventions may be more
likely to be trialled for immediate and short-term out-
comes, and certain non-pharmacological treatment (e.g.
exercise) trials may be more likely to include long-term
outcomes, separate analyses in each time window ensure
that the relative efficacies of competing interventions
will be evaluated in time windows appropriate for how
those interventions are used. When pain ratings have
been collected by the study authors at multiple time
points within a time window, we will use the time point
closest to the median for the immediate and short-term
windows and the longest follow-up for the long-term
follow-up window. If data are not reported at these time
points (but are reported for other time points), we will
make every possible attempt to retrieve these data to re-
duce the possibility of exaggerated treatment effects
from selective reporting of the largest effects [49]. If we
are unable to retrieve the preferred data, we will use out-
comes at the next closest time point but conduct sensi-
tivity analysis excluding these studies.
Effect sizes Odds ratios will be computed for accept-
ability. If sufficient data are available, odds ratios for
pain will also be computed contrasting the number of
treatment responders across two interventions (or an
intervention and control). A responder will be defined as a
patient who demonstrates ≥ 30% and ≥ 50% reduction
from baseline pain rating (we will examine both thresh-
olds separately) reflecting ‘moderate’ and ‘substantial’ clin-
ically important improvement according to IMMPACT
recommendations [22]. When a study does not report
treatment response rate, we will impute these from con-
tinuous pain ratings with an established conversion for-
mula [28, 53], unless an excessive number of imputations
are required given that this imputation assumes a normal
distribution which is usually untestable.
As odds ratios can be difficult to interpret for many
people, we will also present additional statistics generally
perceived as more intuitive. Specifically, we will calculate
risk ratios, absolute risk differences and numbers needed
to treat for primary outcomes, by back transformation of
the odds ratios. The baseline risk value needed for this
transformation will be estimated from random-effects
meta-analysis of risk from the placebo arm of placebo-
controlled trials. For this purpose, we will use a subset
of trials [18] judged to be representative of the overall
population of chronic low back pain patients based on
expert clinical input of the review team.
For pain, we will also calculate effect size as the mean
difference in pain ratings across treatments, as these are
expected to be reported in nearly all studies. If pain rat-
ings are not reported on the usual 0–10 scale, they will
be normalised to this scale. We will use post-treatment
scores to compute effect size, unless only change from
baseline scores are reported in which case we will use
these. Effect sizes using either method can be legitim-
ately pooled [13], and both produce the same effect size
when study pre-treatment scores are equal across groups
(as would be expected here given only randomised de-
signs are eligible). Where we do use change from base-
line scores and standard deviation(s) needed for effect
size computations are not reported, they will be com-
puted in the following priority order: first, using stand-
ard formula [5] based on the change score variance and
the study pre-post correlation (or if unavailable, the
average pre-post correlation across studies that report
it); and second, using the average standard deviation
based on studies that report it.
Secondary outcomes
Based on recommendations for a core outcome set
(COS) in non-specific low back pain [8], we also in-
cluded the following outcomes and associated recom-
mended assessment measures:
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(1) Physical functioning (PF), assessed with the
Oswestry Disability Index 2.1a or Roland-Morris
Disability Questionnaire (the two recommended
COS measures and the most commonly used in tri-
als). If a study does not employ either scale, we will
include any of the following: Quebec Back Pain Dis-
ability Scale, BPI-PI, MPI-PI, SF-36-PF, PROMIS-
PF, CLBPDQ, LBPRS-DI, and ODI 1.0 as there is
evidence of their validity as assessments of PF [8]
(2) Health-related quality of life, assessed with the
Short-Form Health Survey (SF-12/ SF-36) or
PROMIS-GH-10.
(3) Patient or physician ratings of overall improvement.
As all secondary outcomes are assessed on a continu-
ous measure, we will use the mean difference as the ef-
fect size. If an outcome is assessed by multiple different
scales, we will use the most common scale and convert
scores from any other scales to the same metric if an
established mapping algorithm exists. If this results in a
low number of available studies (e.g. < 60% of the total
studies reporting that outcome), to maximise data inclu-
sion, we will standardise all scales for that outcome and
use the standardised mean difference, provided that an
inspection of the domain of the scales suggests the scales
can be meaningfully combined. We will conduct sensi-
tivity analysis in all instances where scales have been
combined.
Outcomes with missing data
Where missing participant data is present, studies may
report analysis on only the subset of patients who ad-
hered to the intervention (per-protocol) or on all partici-
pants who were assigned to the intervention at the start
of the trial (intention-to-treat) after missing data has
been imputed (e.g. using last observation carried for-
ward). If both per-protocol and intention-to-treat ana-
lyses are reported, we will prioritise intention-to-treat
data [54]. In all instances, we will report whether ana-
lysis was conducted on data that were complete,
complete after imputation or incomplete, and we will
examine and report any material differences in results
across these types. When primary outcomes are missing,
an effort will be made to contact authors to obtain data.
Study designs
Only randomised controlled trials comparing an active
intervention with another eligible intervention or control
will be included. Randomisation can be at the individual
or group level, and both parallel group and crossover de-
signs will be included. For crossover designs, only data
from the first trial period will be extracted to eliminate
any possibility of carryover effects.
Language
No language restrictions will be initially applied, al-
though studies for which adequate translation cannot be
obtained will be considered potentially eligible and de-
scribed in the final report but will not be included in the
meta-analysis.
Information sources
We will search for published RCTs indexed in the fol-
lowing databases by the final search date: MEDLINE
(1946-), MEDLINE In-Process, EMBASE (1974-), CEN-
TRAL, CINAHL (1937-), LILACS (1982-) and PsycINFO
(1967-). We will also search for published, unpublished
and ongoing trials in clinical trial registries Clinical-
Trials.gov and WHO International Clinical Trials Regis-
try Platform (ICTRP). We will complement published
data with results reported in these trial registries. We
will additionally search the websites of drug regulatory
bodies of the FDA (USA), MHRA (UK) and EMA (Eur-
ope). It is important to include unpublished data, since
the well-known bias towards publication of significant
findings can, when relying on published literature alone,
lead to an overestimation of treatment effects and an
underestimation of adverse effects [21]. The search strat-
egy will be augmented through hand searching of rele-
vant reviews and of the reference lists of included
articles for additional studies.
For unpublished clinical trials, if a study is listed as on-
going and ≥ 1 year has elapsed since registration, we will
attempt to establish whether the listed trial status is
current. If it emerges that such trials have in fact been
completed or terminated, we will attempt to obtain data
from: (a) the trial registry, (b) study authors, (c) drug
regulatory agency websites and (d) OpenTrials (which
while still in its preliminary stages can provide a wide
range of unpublished evidence including regulatory doc-
uments, clinical study reports and protocols). Where
possible, the same sources will be approached when a
trial has been published but key primary outcomes are
not reported or reported only partially in the journal
publication.
Search strategy
The search strategy was informed by PICOS criteria and
will be comprised of three groups of terms relating to
(1) randomised trials, (2) CLBP and (3) interventions.
Search terms will be combined with a Boolean “AND”
and consist of both controlled subject headings (where
provided by the database) and free-text keywords in ti-
tles and abstracts.
Randomised trials will be identified using highly sensi-
tive search filters validated for each database [23, 31, 41,
58] and CLBP studies identified using search terms sug-
gested by Furlan et al. [26]. For identifying treatments,
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we will employ subject headings for intervention trials
and an extensive list of keywords for specific interven-
tions from clinical practice guidelines [25, 46, 47] and
relevant Cochrane Reviews (https://back.cochrane.org/
our-reviews).
Search strings were reviewed and approved by a
healthcare information specialist at the University of
Greenwich (see Additional file 2 for the draft MEDLINE
example).
Study selection
Records returned by initial searches will be screened for
relevancy in two stages. First, the titles and abstracts of
each record will be independently screened by two
members of the review team, who will exclude studies
not meeting the eligibility criteria. The online software
Rayyan [48] will be used to facilitate first stage screening
by highlighting keywords relating to inclusion and exclu-
sion criteria. Second, the full-text of the remaining arti-
cles will be screened by the same two reviewers, who
will retain for inclusion in the NMA only those that
meet the eligibility criteria. Disagreements at any stage
will be resolved through discussion or, if not resolved,
with a third member of the review team.
Data extraction
Data from each study will be extracted by one member
of the review team and checked for accuracy by a senior
member of the review team, with sets of studies distrib-
uted across a pool of reviewers. We will use a standar-
dised excel coding form adapted from our previous
work, with explanatory notes provided on how coding
should be performed for each variable to ensure
consistency across coders. If there are missing method
data or missing outcome data, the corresponding author
will be contacted via e-mail with one additional re-
minder email sent within 3 weeks if no response is re-
ceived. Subsequently, other authors will be contacted. If
no response is received before analysis is conducted, the
study will be excluded from the NMA but the basic
study findings will be described in a separate section of
the final report. When data are identified as being pub-
lished across multiple sources, we will prioritise extrac-
tion from the most complete data sources. Where these
sources include both published and unpublished data,
we will extract both but prioritise published data in the
analysis as this has been subject to peer-review, but con-
duct sensitivity analysis including both published and
unpublished data.
When available study data do not allow computation
of effect sizes using standard formula (e.g. based on
means and SDs) we will (a) extract other statistics (e.g.
F, p, t) that allow effect sizes to be computed using alter-
native formula [11]; (b) contact study authors for data,
and (c) for missing SDs, use the pooled SD from other
studies [27] or external data. Finally, where a pain rating
scale assesses not only average pain, but least and worst
pain over the previous period (as in the Brief Pain Inven-
tory), we will use only average pain ratings.
Data items
Study information extracted will include (1) study identi-
fiers (e.g. title, authors, publication date); (2) study char-
acteristics (e.g. trial design, source of financial support,
trial size, study location); (3) participant characteristics
(e.g. mean sample age, male/female ratio, SES, pain dur-
ation, severity and current or previous treatments); (4)
intervention details (e.g. type and class of treatment,
intervention details, duration, dosage, delivery method);
and (5) outcome data (including assessment used, tim-
ing, missing data details).
Robustness of findings and risk of bias
Risk of bias will be assessed for all studies using the re-
vised Cochrane Risk of Bias (RoB) tool (RoB 2.0 [54]).
Assessments will be carried out independently by two
reviewers, with any disagreement resolved by discussion
or, if needed, consultation with a third reviewer. We will
also collect additional measures of bias (see “Meta-re-
gression and sensitivity analysis”) and examine their po-
tential influence in meta-regression.
We will conduct threshold analysis [7, 50] to quantify
the level of bias that would have to be present in the es-
timated treatment effect to have resulted in a major
change in treatment ranking (such as a change in the
order of the highest ranked interventions). If the magni-
tude of such potential bias is implausible, then conclu-
sions on the ‘best’ treatments are more robust. If the
level of bias needed to overturn treatment decisions is
plausible, then we will closely examine RoB scores for
that treatment as well as relevant external work to deter-
mine whether such bias is likely to be present to help
evaluate our confidence in the findings.
An alternate method for assessing robustness is Salan-
ti’s [51] GRADE for NMA extension, implemented using
the CINeMA web application. This estimates overall
RoB for a treatment comparison by aggregating individ-
ual study RoB scores after weighting each score based
on a study’s contribution to the overall treatment effect
size. For the proposed NMA, however, we chose
threshold analysis as we will employ a Bayesian analysis
(CINeMA currently applies frequentist weights), and
threshold analysis is more suited to directly informing
treatment decisions [50].
Data synthesis and analysis
We will provide a descriptive table summarising the key
characteristics of each eligible study, including interventions,
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patient populations and trial characteristics. A network dia-
gram will show which intervention classes were compared,
with larger network nodes indicating a greater number of
patients and thicker connecting lines between nodes indicat-
ing a greater number of trials.
Consistency assumption
A key assumption of NMA is that each participant
should be equally likely to have received any of the treat-
ments in the network. If this assumption holds, a key
consequence is that there should be no systematic differ-
ences in effect modifiers (such as important patient
characteristics) across different sets of treatment com-
parisons that might otherwise explain apparent interven-
tion differences [10].
As described in the “Population” section, we will en-
sure similarity by restricting patient populations to those
with non-specific LBP that is chronic only and who re-
port a moderate or greater level of pain. We will also
qualitatively assess the clinical similarity of populations
across different treatment comparisons on potentially
important factors, such as age, sex, baseline pain severity
and CLBP duration [3, 32, 40], and present this in a
summary table. Statistical tests of consistency we will
employ are described in the “Assessment of consistency”
and the “Assessment of within-comparison heterogen-
eity” sections. One common concern with comparing
pharmacological and non-pharmacological interventions
in general is that one class of intervention is adminis-
tered as a first-line treatment and the other is given to
treatment-resistant cases for whom previous interven-
tions have failed. Because we are examining chronic
LBP, however, treatment failure would have been likely
for all patients during the acute phase of their LBP in
order for chronic LBP to develop.
Network meta-analysis
We will conduct a Bayesian NMA to estimate relative
treatment effects based on a synthesis of direct (head-to-
head trials) and indirect evidence (where two treatments
are compared indirectly via a common comparator). We
will use a class-based hierarchical model [18] to estimate
the relative effects of different treatment classes (e.g.
NSAIDs, opioids) and of individual treatments within a
class (e.g. ibuprofen, aspirin, diclofenac). Pharmacological
and non-pharmacological studies may differ in patient and
study characteristics and type of biases that may exist. As
such, we will conduct separate analyses of these two net-
works along with an analysis of the whole network (pro-
viding head-to-head comparisons of pharmacological and
non-pharmacological interventions are available) to see if
these two approaches yield similar results.
The relative effectiveness of different treatments will
be modelled as a function of their performance relative
to a placebo reference treatment. This will be presented
as a forest plot for class effects and in table form for
class and individual effects. Mean ranks with their 95%
credible intervals and SUCRA (a simple transformation
of the mean rank) will be used to provide a hierarchy of
the best treatments.
Estimation details
Model parameters will be estimated in WinBUGS using
Markov Chain Monte Carlo simulation. Posterior distri-
butions will be derived from binomial (binary outcomes)
and normal (continuous) likelihood functions using
vague prior distributions. For within-treatment study
variability, we will assume a common heterogeneity
standard deviation and use a partially informative uni-
form prior with an upper bound limit based on the out-
come scale used (e.g. U(0, 10) for pain ratings). For
within-class variability (of treatments), we will use a uni-
form prior distribution estimated separately for each
class. However, for classes with only a few elements, de-
cisions will be made on whether the within-class vari-
ance estimates can be shared across similar classes (e.g.
SNRI and SSRI classes). For other parameters, we will
use wide non-informative normal priors. We will exam-
ine Gelman-Rubin trace plots to check that multiple
chains achieve convergence during the burn-in period,
and base our estimates on 50,000 or more subsequent it-
erations to ensure MC estimator error is less than 5% of
the standard deviation for the treatment effect and het-
erogeneity parameters. With respect to multi-arm trials,
the correlation between multiple treatment comparisons
within these trials is naturally accounted for within the
Bayesian framework.
The choice between a random-effects (RE) and fixed-
effect (FE) model will be informed by a comparison of
Deviance Information Criteria (DIC) model fit statistics.
If the DIC for the RE model is at least 3 units lower
(with lower values indicating better fit) [18], we will use
a RE model. If the models are otherwise similar, we will
choose the more parsimonious FE model provided there
is no excessive study heterogeneity from separate pair-
wise analysis.
Assessment of consistency
We will assess whether there is consistency of direct and
indirect evidence globally across the whole network
(which is a natural consequence of the similarity as-
sumption) using the unrelated mean effects model [17].
If evidence of inconsistency is found, we will use a node-
splitting approach [16] to identify possible areas of local
inconsistency and, if sufficient data exist, run network
meta-regression to examine whether inconsistency (and
study heterogeneity) is resolved by a consideration of
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differences in clinical variables (the “Consistency as-
sumption” section).
In the event of minor unresolved inconsistency, we
will proceed with NMA but advise caution in the inter-
pretation of results for comparisons where there are ma-
terial differences between direct and indirect estimates.
If there is evidence of substantive inconsistency, we will
consider excluding network nodes.
Assessment of within-comparison heterogeneity
Study heterogeneity within each treatment comparison
will be examined with forest plots from pairwise meta-
analysis for an initial visual assessment (and these will
be used to alert us to potential outliers). We will also
compute I2, which indicates the proportion of overall
variance in effect sizes due to genuine heterogeneity. I2
> 60% can indicate a moderate or greater variation in
study effect sizes [34] and will be explored with meta-
regression. We will also compute Cochran’s Q with p <
.10 used to indicate possible presence of heterogeneity
and tau-squared to provide an estimate of effect size het-
erogeneity for different comparisons
Meta-regression and sensitivity analysis
Given sufficient data, we will use network meta-
regression to explore whether inconsistency/heterogen-
eity and group differences in the two primary outcomes
is influenced by potential biases such as industry spon-
sorship, performance in less (vs. more) developed coun-
tries [14], risk of bias scores, novel agent effects [52] and
researcher allegiance to the study intervention [20]. Two
members of the review team will independently assess
researcher allegiance (with any disagreement resolved by
consensus) using a checklist developed and piloted for
the current study (Additional file 3) based on the modi-
fied reprint method [44]. We will also include effect size
derivation method (post vs. change scores) as a dummy-
coded covariate to check that effect sizes from both
methods are similar.
We will produce treatment-control comparison-
adjusted funnel plots to explore possible publication
bias, and if bias is suspected explore this by including
sample size as a covariate. We will also perform a test of
excess significance [36] which is applied to data aggre-
gated across the whole network of interventions (thus
offering higher statistical power than pairwise tests) to
assess whether there is an excess of statistically signifi-
cant findings.
We will also assess the robustness of the findings to
various decisions by performing sensitivity analyses in-
cluding removing studies (a) with high risk of bias, (b)
where imputations have been performed, (c) where we
assumed LBP was non-specific when this could not be
definitively determined (the “Population”section), and
(d) where very high/low dosages were used for off label
medications. In addition, we will rerun the analysis after
reclassifying McKenzie therapy into mind-body aware-
ness exercises based on feedback from the Lancet LBP
working group.
Unit of analysis issues
For trials that use cluster randomisation without adjust-
ing standard errors for the study’s design effect [35], we
will apply this adjustment ourselves. As intra-class corre-
lations needed to make this correction are seldom re-
ported, we will use values obtained from external
literature for the outcome examined (or if these are not
available use a single plausible value and examine the
impact of varying this value in sensitivity analysis).
Discussion
The results from this NMA will provide an important
evidence base for clinicians to inform treatment deci-
sions by providing a comparative assessment of a wide
range of interventions [55]. This will help efforts to de-
velop a precision medicine approach to the treatment
for non-specific chronic low back pain, which can be
used in everyday clinical settings. While there are nu-
merous factors that must be considered in treatment de-
cisions, such as cost-effectiveness, individual patient
suitability and patient preferences [37], reliable informa-
tion on the pain-relieving effects and acceptability of a
treatment as well as an assessment of how bias-free
these results might be are fundamental points in guiding
these decisions.
Given the sheer scale of the burden of chronic low back
pain, we expect the results of the NMA to be of consider-
able interest to clinicians, academics, guideline developers
and policymakers [38] and we will disseminate the findings
widely through academic publications, conference presenta-
tions and communication with healthcare providers.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01398-3.
Additional file 1. PRISMA-P checklist.
Additional file 2. MEDLINE search string.
Additional file 3. Researcher allegiance.
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